Eli Lilly Acquires Centessa Pharmaceuticals: Market Analysis
Decision brief
Answer first · skim in under a minute
Eli Lilly has announced its acquisition of Centessa Pharmaceuticals for $7.8 billion. This strategic move is set to reshape the pharmaceutical landscape.
Eli Lilly and Centessa Pharmaceuticals announced a definitive acquisition agreement on March 31, 2026, centered on Centessa’s orexin receptor agonist pipeline for sleep-wake disorders. Deal math is precise in the joint release and Centessa’s SEC Form 8-K: $38.00 cash per share plus a CVR of up to $9.00, or roughly $6.3 billion upfront and about $7.8 billion including contingent value.
Contents10 sections
Key Takeaways
- Announcement date: March 31, 2026; structure is an English-law scheme of arrangement, not a simple U.S. tender-only buyout.
- Cash at closing: $38.00 per share (~$6.3 billion aggregate equity value), a ~40.5% premium to Centessa’s 30-day VWAP ended March 30, 2026.
- CVR up to $9.00 per share (~$1.5 billion potential) tied to FDA approvals of cleminorexton or ORX142 in specified sleep indications.
- High Court sanction reported June 22, 2026, with effectiveness expected around June 24, 2026 after registrar filing.
What did Lilly and Centessa announce on March 31, 2026?
Lilly (NYSE: LLY) and Centessa (Nasdaq: CNTA) said Lilly would acquire all Centessa share capital, including ADSs, for $38.00 in cash per share plus one non-transferable contingent value right. Total potential consideration is up to $47.00 per share. Centessa develops medicines for excessive daytime sleepiness and related neurological conditions. The companies described the combination as advancing treatments for sleep-wake disorders through Centessa’s orexin platform.
See the March 31, 2026 PR Newswire joint release and Centessa’s Form 8-K filed on SEC EDGAR.
How is the CVR structured?
CVR holders can receive contingent cash if milestones hit: $2.00 upon U.S. FDA approval of cleminorexton (formerly ORX750) or ORX142 for narcolepsy type 2 before the fifth anniversary of closing; $5.00 upon FDA approval of either for idiopathic hypersomnia on the same five-year clock; and $2.00 upon the first U.S. FDA approval of either for any indication before January 1, 2030. The companies state there is no assurance any CVR payment will be made. That contingency is why “$7.8 billion” is a total potential value, not guaranteed consideration.
What closing path and timing should BD teams track?
The transaction uses a court-sanctioned scheme of arrangement under English law. Closing was initially guided to the third quarter of 2026, subject to Centessa shareholder approval, High Court sanction, and customary regulatory conditions. On June 22, 2026, Centessa announced High Court approval and said the scheme would become effective upon delivering the court order to the Registrar of Companies, expected June 24, 2026, with Nasdaq trading halt timing around that date.
Court update: June 22, 2026 GlobeNewswire High Court sanction release.
Why this deal matters for neuroscience competitive dynamics
Large-cap buyers have treated orexin receptor 2 agonists as strategic sleep-wake assets. Lilly’s willingness to pay a ~40% VWAP premium plus indication-tied CVRs signals scarcity pricing for differentiated CNS sleep programs. Rival BD teams should reassess remaining clinical-stage orexin and hypersomnia assets for competitive auction risk rather than assuming 2026 neuroscience M&A remains GLP-1 dominated.
Data points for deal models
- Announcement: March 31, 2026
- Cash: $38.00/share; CVR: up to $9.00/share
- Upfront equity value: ~$6.3 billion; CVR potential: ~$1.5 billion
- Premium: ~40.5% to 30-day VWAP through March 30, 2026
- Court sanction: June 22, 2026
What remains unproven
CVR payments depend on future FDA approvals that have not occurred. Peak-sales projections for cleminorexton or ORX142 are not in the primary releases and are omitted here. Prior draft language that treated the $7.8 billion figure as locked cash consideration without explaining the CVR is corrected.
Related NovaPharma coverage
- Eli Lilly Pipeline and Deals: 2026 Outlook
- AbbVie Cerevel $8.7B Neuroscience Acquisition
- Lilly Buys 4E in Non-Opioid Pain Push
Frequently Asked Questions
What are the headline economics of Lilly buying Centessa?
On March 31, 2026, Lilly and Centessa announced $38.00 cash per share plus a non-transferable CVR worth up to $9.00, or up to $47.00 per share total. Upfront equity value is about $6.3 billion; including CVR potential the companies cite roughly $7.8 billion.
What assets is Lilly buying in the Centessa deal?
Centessa is a clinical-stage company focused on orexin receptor 2 agonists for excessive daytime sleepiness and related neurological conditions, including cleminorexton (formerly ORX750) and ORX142. CVR milestones are tied to FDA approvals in narcolepsy type 2, idiopathic hypersomnia, and any first U.S. approval before January 1, 2030.
When did the Centessa scheme receive court approval?
Centessa reported on June 22, 2026, that the High Court of Justice of England and Wales sanctioned the scheme of arrangement. Closing was expected after delivery of the court order to the Registrar of Companies around June 24, 2026.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
